Library - Page 7
Registered on ClinicalTrials
Mexidol in the complex treatment of glaucoma
Author:
E.A. EGOROV, N.G. DAVYDOVA, I.A. ROMANENKO, N.D. NOVIKOVA
RNIMU named after N.I. Pirogov, GB of GB named after Helmholtz, Moscow
Mexidol in the complex therapy of stable angina pectoris
Authors:
G. I. NECHAYEVA1, S. D. KUROCHKINA2, A. D. TROTSENKO3, E. Yu. BULAKHOVA2
1Omsk State Medical Academy
2BUKOO City Clinical Hospital No. 4
3BUKOO Medical Center of the Ministry of Health of Omsk Region
International multicenteric randomized double-tied placebo-controlled study of evaluating the effectiveness and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol® and Mexidol® Forte 250 (study of memo): Subanalysis results in patients with arterial hypertension
V.V. ZAKHAROV1, O.D. OSTROUMOVA1,2, A.I. KOCHETKOV2, M.V. KLEPIKOVA2, A.I. FEDIN3
1Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Russian Ministry of Health (Sechenov University);
2Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Russian Ministry of Health, Moscow;
3Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Russian Ministry of Health, Moscow
Place of publication:
THERAPY No. 1 (63) 2023
To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate
Authors:
A.I. KOCHETKOV, N.A. SHATALOVA, M.V. KLEPIKOVA, T.V. FILIPPOVA, O.D. OSTROUMOVA
Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Health of the Russian Federation, Moscow
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
Zakharov V.V. 1*, Tkacheva O.N. 2*, 3*, Mkhitaryan E.A. 2*, 3*, Fedin A.I. 2*
1* I.M. Sechenov First Moscow State Medical University of the Russian Ministry of Healthcare
(Sechenov University), Moscow, Russia;
2* N.I. Pirogov Russian National Research Medical University of the Russian Ministry of Healthcare,
Moscow, Russia;
3* Russian Gerontology Research and Clinical Center of N.I. Pirogov Russian National Research
Medical University of the Russian Ministry of Healthcare, Moscow, Russia
Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry
2022, Vol. 122, No. 11, Issue 2, pp. 73–80
Promising Effects of Emoxypine and Its Succinate Derivate in the Management of Various Disess-Withs on Recent Patent Applications
Dhruv Sanjay Gupta, Siddhi Bagwe Parab, Ginpreet Kaur
Translated from Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova, Vol. 121, No. 12, Iss. 2, pp. 69–76,
December, 2021. Original article submitted December 20, 2021. Accepted December 22, 2021.
Publication location:
Neuroscience and Behavioral Physiology, Vol. 52, No. 5, June 2022
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Registered on ClinicalTrials
A.I. FEDIN1, V.V. ZAKHAROV2, M.M. TANASHYAN3, E.I. CHUKANOVA1, E.N. MAJIDOVA4, L.A. SCHEPANKEVICH5.6, O.D. OSTROUMOVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2I.M. Sechenov First Moscow Medical University,
3Neurology Research Center,
4, Russia;
5Novosibirsk State Medical University, Novosibirsk
6Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
7Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 11
Neuroprotection for cerebral disasters at the stage of ambulance
Authors:
V.L. RADUSHKEVICH, A.I. OKUNEVSKY
FSBEI in Voronezh State Medical University named after N. N. Burdenko "of the Ministry of Health of Russia, Voronezh
Place of publication:
MEDICAL ALPHABET No. 19/2017, VOLUME No. 3. EMERGENCY MEDICINE
Original and reproduced drugs: what do the clinician need to know?
Author:
A.V. SHCHULKIN, A.A. FILIMONOVA
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University” of the Ministry of Health of the Russian Federation, Ryazan, Russia
Reproduced drugs: Benefit ratio/risk
E.A. USHKALOVA1, S.K. ZYRYANOV1,2, I.A. GOPIENKO1
1Peoples’ Friendship University of Russia, Moscow;
2City Clinical Hospital No. 24 of the Moscow Department of Health, Moscow
The use of Mexidol in intensive therapy of acute severe ischemic stroke
Authors:
Seryogin V.I., Dronova T.V.
GBU RO "Skopinskaya Central District Hospital", Ryazan Region, Russia
Place of publication:
Journal of Neurology and Psychiatry, 3, 2015; Ext. 2
Pharmacoeconomic analysis of neuroprotectors used in the treatment of ischemic stroke
Authors:
R.I. YAGUDINA1, A.Yu. KULIKOV1, V.A. KRYLOV1, E.Yu. SOLOVYEVA2, A.I. FEDIN2
1Federal State Budgetary Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Russian Ministry of Health (Sechenov University), Moscow, Russia;
2Federal State Budgetary Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Russian Ministry of Health, Moscow, Russia
Modern ideas about the antihypoxic and antioxidant effects of Mexidol
Author:
A.V. SHCHULKIN
Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi Cace and Safety of Mexidol in Prolonged Sequential Therapy of Patient S in the Acute and Early Recovery Stages of Hemisphereic Stroke (The Epica Study)
Authors:
LV Stakhovskaya1, NA Shamalov1, DR Khasanova2, EV Melnikova3, AS Agafina4, KV Golikov5, EI Bogdanov6, AA Yakupova6, LV Roshkovskaya7, LV Lukinykh8, TM Lokshtanova9, IE Poverennova10, LA Shchepankevich11
1ResearchInstitute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
2Interregional Clinical Diagnostic Center, Kazan, Russia.
3St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.
4St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.
5St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.
6Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.
7Nikolaevskaya Hospital, St. Petersburg, Russia.
8Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.
9Pirogov City Clinical Hospital No. 1, Samara, Russia.
10Seredavin Samara Regional Clinical Hospital, Samara, Russia.
11Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.
Publication place:
NEUROSCIENCE AND BEHAVIORAL PHYSIOLOGY, VOL. 48, NO. 8, OCTOBER, 2018
Vegetative dysfunction in patients with cerebrovascular diseases and metabolic syndrome
Author:
V.N. SHISHKOVA
, Federal State Budgetary Institution National Medical Research Center for Therapeutic and Preventive Medicine, Ministry of Health of the Russian Federation, Moscow, Russia
The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure
Registered on ClinicalTrials
A.A. BELKIN, V.A. BELKIN, I.E. VASILCENKO, E.A. PINCHUK
ANO "Clinical Institute of the Brain", Sverdlovsk region, Berezovsky, Russia
Link to the study here
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2024, Vol. 124, No. 4
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com